Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

KZKeshu ZhouDZDehui ZouLLLanfang Li

Discussion

Loading...

Member takes

Overview

Real-world analysis demonstrates improved progression-free survival in older patients with R/R NHL, indicating broad applicability of CAR-T therapy.

Key Points

  • To evaluate the effectiveness and safety of axi-cel in different age groups of Chinese patients with relapsed/refractory non-Hodgkin lymphoma.
  • Analysis of outcomes comparing patients aged ≥65 and <65 from 20 Chinese centers.
  • Patients received commercially available axi-cel targeting a dose of 2×10⁶ CAR-T cells/kg.
  • Endpoints were overall survival, best objective response rate, best complete response rate, and progression-free survival.
  • Older patients (≥65) showed higher complete response rates (78.4% vs. 60.6%).
  • The 9-month progression-free survival rate for older patients was 66.7% compared to 59.4% for younger patients.
  • Adverse event rates were similar between age groups, although older patients had a higher incidence of grade ≥3 cytokine release syndrome.

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d91dhttps://doi.org/10.1182/blood-2025-7230
View Full Paper
Ask AI
Bookmark
Share